Autolus appoints Mike Bonney as Chair and Ravi Rao as director; John Johnson resigns effective April 1, 2024

Autolus Therapeutics plc

John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.
Mike Bonney appointed Chairman of the Board; over 30 years biotech experience, formerly CEO of Cubist Pharmaceuticals.
Ravi Rao, M.D. appointed Non-Executive Director; current CMO of Sitryx and previous CMO at Oxford Biomedica.
Board changes effective April 1, 2024; Bonney and Rao receive annual retainers and initial option awards.
Press release notes recent FDA acceptance of BLA for obe-cel in r/r adult B-cell ALL as key company milestone.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Johnson

Chairman of the Board

AUTL · Autolus Therapeutics plc

Effective: 2024-04-01
Successor: Michael Bonney
Filed: April 1, 2024, 7:59 PM ET

On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.

Appointed

Michael Bonney

Chairman of the Board

AUTL · Autolus Therapeutics plc

Effective: 2024-04-01
Filed: April 1, 2024, 7:59 PM ET

appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.

Appointed

Ravi Rao

Non-Executive Director

AUTL · Autolus Therapeutics plc

Effective: 2024-04-01
Filed: April 1, 2024, 7:59 PM ET

appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Johnson resigned as Chairman of the Board at Autolus Therapeutics plc.

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Bonney was appointed as Chairman of the Board at Autolus Therapeutics plc.

Action: appointed
Role: Chairman of the Board

Exact text from the filing

appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ravi Rao was appointed as Non-Executive Director at Autolus Therapeutics plc.

Action: appointed
Role: Non-Executive Director

Exact text from the filing

appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.

View on SEC.gov

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.